AzTrials
AzTrials

Adult Onset Still DiseaseMAOSDCNCT03651193

Multi-center Registration Study of Adult Onset Still's Disease in Chinese Population

An observational study of Adult Onset Still Disease, run by Second Xiangya Hospital of Central South University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This multi-center registration study will investigate the clinical characteristics of AOSD population in China , identify possible factors inducing the onset and active condition of AOSD in Chinese population , and identify the new high specific and sensitive markers of AOSD Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Adult Onset Still Disease
What is being tested?
Exon sequencing and Methylated sequencing
How many people
150 participants
Where
1 siteChina
Study dates
28 Nov 2018to 31 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Chinese population

Who may be able to join

  • AOSD: Patients fulfill Japan's Yamaguch AOSD classification.
  • Control: Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.

Who cannot join

  • Anyone with physical or mental illness that may affect the assessment will be excluded, such as patients with hearing or speech expression disorders.

Trial locations and contacts

1 site in 1 country.

Qianjin Lu, MD,PHD contact

+86-13787097676

qianlu5860@gmail.com

China1 site, 1 recruiting
  • The Second Xiangya Hospital of Central South University

    Hunan, Changsha, 410011

    Xiangqi Tang, MD, PhD, +86-731-84896038, xiangyagcp@126.com

    Qianjin Lu, MD, PhD

    Recruiting

Other trials in China

About this study

This multi-center registration study will investigate the clinical characteristics of AOSD population in China , identify possible factors inducing the onset and active condition of AOSD in Chinese population , and identify the new high specific and sensitive markers of AOSD

Read the detailed description

Backgrounds: Adult-onset Still's disease (AOSD) is a rare systemic clinical syndrome of unknown etiology. Its pathogenesis is complex, often thought to be affected by infection, genetic and immune factors. Due to the low incidence of adult Still's disease and the lack of specific clinical features and laboratory tests, infections, tumors, connective tissue diseases and other diseases must be excluded before clinical diagnosis. Therefore, the diagnosis of adult Still's disease is still a great challenge for clinicians at this stage. Moreover, the process of exclusion diagnosis is long, and examinations, including some invasive examinations, are bringing heavy burden to the patients psychologically, physiologically and economically.

The clinical manifestations of AOSD vary greatly, and AOSD is typically characterised by spiking fever, arthritis, evanescent rash. Other non-specific symptoms may be observed in AOSD: involvement of lymphatic/reticuloendothelial system can cause sore throat, lymph node enlargement; involvement of respiratory and cardiovascular system can cause chest pain and dyspnea; involvement of the liver can cause liver enlargement and abnormal liver function. In addition, it can involve all major systems of the body. Common laboratory indicators include: WBC> 10 000 / mm3, with neutrophils> 80%, abnormal increased erythrocyte sedimentation rate (ESR) and C-reactive protein (90% - 100% in AOSD), Hyperferritinemia ( specificity of 80%) and IL-18 (sensitivity of 91.7% and specificity of 99.1%). However, both clinical symptoms and laboratory examinations are not unique to the disease, and infections, tumors, connective tissue diseases and so on often exhibit similar characteristics. Therefore, these diseases need to be excluded before the diagnosis of adult Still's disease in order to prevent delays in diagnosis and missing the best opportunity for treatment .

At present, the treatment of AOSD is usually empirical and diagnostic, mainly using NSAIDs, steroids, DMARDS and biological agents. Although these treatments can effectively relieve symptoms and improve the quality of life of patients, but still cannot cure the disease. A small number of patients can be remitted within a year and no longer relapse; about one-third of patients relapse several times in uncertain interval , with lighter symptoms and shorter duration than the initial onset after complete remission ; the rest of the patients will be chronic. Besides, a small number of serious patients will develop into macrophages. Activation syndrome often threatens life. Therefore, most patients need long-term monitoring and even lifelong medication.

At present, there is no national study on AOSD with large sample size in China, and many foreign studies on the potential biomarkers of AOSD still need to be further explored in terms of sensitivity and specificity. The investigators carried out this study to collect at least 150 pairs of clinical data and blood samples from patients with AOSD and age-and sex-matched normal controls through collaboration of multiple units throughout the country, and to perform genome-wide exon sequencing and methylation sequencing in order to identify the genetic and epigenetic characteristics of specific changes in AOSD. On this basis, further studies on pathogenesis are carried out.The results of this study may reveal the main pathogenesis of adult Still's disease, identify potential biomarkers with high sensitivity and specificity in peripheral blood, thus simplifying the diagnostic process, shortening the diagnostic cycle, reducing invasive examinations, alleviating the psychological, physiological and economic burden of patients in the diagnostic process, and providing AOSD with a new direction for diagnosis and treatment.

Design of Study: This is a cross sectional survey and 1:1 case-control study to explore the clinical characteristics of AOSD population in China; Identify possible factors inducing the onset and active condition of AOSD in Chinese population ;Identify new markers of AOSD with high specificity and sensitivity.

Methods: Pre-experiment preparation: design data collection form, determine the final data collection form and experimental plan, establish multiple experimental centers across the country.

After sample screening, informed consent, determine join in this study or not. Divide those population agree to join into AOSD group and Controlled group(1:1 matching). Then carry out Case study, case-control study and disease impact investigation among AOSD group, carry out case-control study and disease impact investigation among controlled group. Case study include investigating characteristics and relationship between AOSD and exposure factors among AOSD group. Case-control study is comprised of study of living environment and dietary exposure, social, and psychological factors ,behavior, genetics, epigenetics, immunology, biomarkers. Disease impact investigation covers Psychological emotion , social burden and quality of life. The results are to analyzed using multivariate logistic regression analysis: overall factors.

Being tested
Exon sequencing and Methylated sequencing
Keywords
Adult Onset Still's Disease, Chinese population
Medical subject headings
Still's Disease, Adult-Onset

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exon sequencing and Methylated sequencingDiagnostic test

    Exon sequencing and Methylated sequencing

Study groups in NCT03651193
Study groupRoleWhat they receive
AOSDPatients fulfill Japan's Yamaguch AOSD classification
Receives: Diagnostic Test: Exon sequencing and Methylated sequencing
ControlUse 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
Receives: Diagnostic Test: Exon sequencing and Methylated sequencing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. gene expression level and methylation level

    The data of this study is managed by the Hunan Key Laboratory of Medical Epigenomics (Department of Dermatology, The Second Xiangya Hospital of Central South University). The authenticity, integrity and confidentiality of clinical data are required to be ensured, original case and case report form shall be filled out by investigator or the designated person of researcher and shall not be altered at will. If necessary, the name of the changer and the date of modification should be signed.

    Statistical analysis will use GraphPad Prism or SPSS software. All statistical tests will be performed using a two-sided test, P values less than 0.05 will be considered statistically significant, the confidence interval uses 95%. The measurement data will be statistically described using mean ± standard deviation or median (minimum, maximum). Disease exposure factors and impact analysis will be based on descriptive statistical analysis.

    Measured: 0 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Aug 2018
  2. Study start28 Nov 2018
  3. Primary completion30 Jun 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03651193
Sponsor's protocol ID
MAOSDC20180720
Acronym
MAOSDC
Status last verified
Jan 2021
First submitted
27 Aug 2018
Last updated
2 Feb 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Adult Onset Still Disease, run by Second Xiangya Hospital of Central South University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Qianjin Lu, MD,PHD (+86-13787097676, qianlu5860@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

gene expression level and methylation level (time frame: 0 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in